CLCaryn Lerman

Caryn Lerman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caryn Lerman has a total of 187 co-authors. Here are the top co-authors by number of shared publications:

  • Freda Patterson

    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

    13 shared publications
  • Christopher Jepson

    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

    9 shared publications
  • E. Paul Wileyto

    Center for Interdisciplinary Research on Nicotine Addiction, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104

    8 shared publications
  • Janet Audrain

    8 shared publications
  • Riju Ray

    Center for Interdisciplinary Research on Nicotine Addiction, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA

    8 shared publications
  • Angela Pinto

    Department of Psychiatry, Transdisciplinary Tobacco Use Research Center, University of Pennsylvania Philadelphia, PA

    6 shared publications

Latest Publications

  • Open Access

    Measures and predictors of varenicline adherence in the treatment of nicotine dependence

    by Annie R. Peng, Mark Morales, E. Paul Wileyto, Larry W. Hawk, Paul Cinciripini, Tony P. George, Neal L. Benowitz, Nicole L. Nollen, Caryn Lerman, Rachel F. Tyndale, et al.


  • Open Access

    RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles

    by Amy Webb, Audrey C. Papp, Amanda Curtis, Leslie C. Newman, Maciej Pietrzak, Michal Seweryn, Samuel K. Handelman, Grzegorz A. Rempala, Daqing Wang, Erica Graziosa, et al.

    We used RNA sequencing to analyze transcript profiles of ten autopsy brain regions from ten subjects. RNA sequencing techniques were designed to detect both coding and non-coding RNA, splice isoform composition, and allelic expression. Brain regions were selected from five subjects with a documented history of smoking and five non-smokers. Paired-end RNA sequencing was performed on SOLiD instruments to a depth of >40 million reads, using linearly amplified, ribosomally depleted RNA. Sequencing libraries were prepared with both poly-dT and random hexamer primers to detect all RNA classes, including long non-coding (lncRNA), intronic and intergenic transcripts, and transcripts lacking poly-A tails, providing additional data not previously available. The study was designed to generate a database of the complete transcriptomes in brain region for gene network analyses and discovery of regulatory variants. Of 20,318 protein coding and 18,080 lncRNA genes annotated from GENCODE and lncipedia, 12 thousand protein coding and 2 thousand lncRNA transcripts were detectable at a conservative threshold. Of the aligned reads, 52 % were exonic, 34 % intronic and 14 % intergenic. A majority of protein coding genes (65 %) was expressed in all regions, whereas ncRNAs displayed a more restricted distribution. Profiles of RNA isoforms varied across brain regions and subjects at multiple gene loci, with neurexin 3 (NRXN3) a prominent example. Allelic RNA ratios deviating from unity were identified in > 400 genes, detectable in both protein-coding and non-coding genes, indicating the presence of cis-acting regulatory variants. Mathematical modeling was used to identify RNAs stably expressed in all brain regions (serving as potential markers for normalizing expression levels), linked to basic cellular functions. An initial analysis of differential expression analysis between smokers and nonsmokers implicated a number of genes, several previously associated with nicotine exposure. RNA sequencing identifies distinct and consistent differences in gene expression between brain regions, with non-coding RNA displaying greater diversity between brain regions than mRNAs. Numerous RNAs exhibit robust allele selective expression, proving a means for discovery of cis-acting regulatory factors with potential clinical relevance.


  • Translational Research on Nicotine Dependence

    by Mary Falcone, Bridgin Lee, Caryn Lerman, Julie A. Blendy

    Nicotine dependence is a chronic, relapsing disorder with complex biological mechanisms underlying the motivational basis for this behavior. Although more than 70 % of current smokers express a desire to quit, most relapse within one year, underscoring the need for novel treatments. A key focus of translational research models addressing nicotine dependence has been on cross-validation of human and animal models in order to improve the predictive value of medication screening paradigms. In this chapter, we review several lines of research highlighting the utility of cross-validation models in elucidating the biological underpinnings of nicotine reward and reinforcement, identifying factors which may influence individual response to treatment, and facilitating rapid translation of findings to practice.


  • Human Mu Opioid Receptor ( OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers

    by Riju Ray, Kosha Ruparel, Andrew Newberg, E. Paul Wileyto, James W. Loughead, Chaitanya Divgi, Julie A. Blendy, Jean Logan, Jon-Kar Zubieta, Caryn Lerman

    Evidence points to the endogenous opioid system, and the mu-opioid receptor (MOR) in particular, in mediating the rewarding effects of drugs of abuse, including nicotine. A single nucleotide polymorphism (SNP) in the human MOR gene (OPRM1 A118G) has been shown to alter receptor protein level in preclinical models and smoking behavior in humans. To clarify the underlying mechanisms for these associations, we conducted an in vivo investigation of the effects of OPRM1 A118G genotype on MOR binding potential (BPND or receptor availability). Twenty-two smokers prescreened for genotype (12 A/A, 10 */G) completed two [11C]carfentanil positron emission tomography (PET) imaging sessions following overnight abstinence and exposure to a nicotine-containing cigarette and a denicotinized cigarette. Independent of session, smokers homozygous for the wild-type OPRM1 A allele exhibited significantly higher levels of MOR BPND than smokers carrying the G allele in bilateral amygdala, left thalamus, and left anterior cingulate cortex. Among G allele carriers, the extent of subjective reward difference (denicotinized versus nicotine cigarette) was associated significantly with MOR BPND difference in right amygdala, caudate, anterior cingulate cortex, and thalamus. Future translational investigations can elucidate the role of MORs in nicotine addiction, which may lead to development of novel therapeutics.


  • Nicotine

    by Freda Patterson, Robert A. Schnoll, Caryn Lerman

  • Nicotine Dependence and Pharmacogenetics

    by Riju Ray, Robert Schnoll, Caryn Lerman


  • Reinforcing Effects of Smoking: More Than a Feeling

    by Caryn Lerman, Janet Audrain-McGovern


  • Genetic Variation in Nicotine Metabolism Predicts the Efficacy of Extended-Duration Transdermal Nicotine Therapy

    by C Lerman, C Jepson, E P Wileyto, F Patterson, R Schnoll, M Mroziewicz, N Benowitz, R F Tyndale

    In a placebo‐controlled trial, we examined the efficacy of a 6‐month (“extended”) transdermal nicotine therapy vs. the 8‐week (“standard”) therapy in 471 Caucasian smokers with either normal or reduced rates of nicotine metabolism as determined at pretreatment. Extended therapy was superior to standard therapy in genotypic or phenotypic reduced metabolizers (RMs) of nicotine but not in normal metabolizers (NMs). RMs of nicotine are candidates for extended transdermal nicotine therapy, whereas an alternative therapeutic approach may be needed for those with normal rates of nicotine metabolism. Clinical Pharmacology & Therapeutics (2010) 87 5, 553–557. doi: 10.1038/clpt.2010.3


  • Open Access

    Convergent Evidence that Choline Acetyltransferase Gene Variation is Associated with Prospective Smoking Cessation and Nicotine Dependence

    by Riju Ray, Nandita Mitra, Don Baldwin, Mengye Guo, Freda Patterson, Daniel F Heitjan, Christopher Jepson, E Paul Wileyto, Jinxue Wei, Thomas Payne, et al.

    The ability to quit smoking is heritable, yet few genetic studies have investigated prospective smoking cessation. We conducted a systems-based genetic association analysis in a sample of 472 treatment-seeking smokers of European ancestry after 8 weeks of transdermal nicotine therapy for smoking cessation. The genotyping panel included 169 single-nucleotide polymorphisms (SNPs) in 7 nicotinic acetylcholine receptor subunit genes and 4 genes in the endogenous cholinergic system. The primary outcome was smoking cessation (biochemically confirmed) at the end of treatment. SNPs clustered in the choline acetyltransferase (ChAT) gene were individually identified as nominally significant, and a 5-SNP haplotype (block 6) in ChAT was found to be significantly associated with quitting success. Single SNPs in ChAT haplotype block 2 were also associated with pretreatment levels of nicotine dependence in this cohort. To replicate associations of SNPs in haplotype blocks 2 and 6 of ChAT with nicotine dependence in a non-treatment-seeking cohort, we used data from an independent community-based sample of 629 smokers representing 200 families of European ancestry. Significant SNP and haplotype associations were identified for multiple measures of nicotine dependence. Although the effect sizes in both cohorts are modest, converging data across cohorts and phenotypes suggest that ChAT may be involved in nicotine dependence and ability to quit smoking. Additional sequencing and characterization of ChAT may reveal functional variants that contribute to nicotine dependence and smoking cessation.


  • Effectiveness of Extended-Duration Transdermal Nicotine Therapy

    by Robert A. Schnoll, Freda Patterson, E. Paul Wileyto, Daniel F. Heitjan, Alexandra E. Shields, David A. Asch, Caryn Lerman

    Schnoll and associates assessed whether extended-duration transdermal nicotine therapy (21 mg for 24 weeks) increased abstinence from tobacco more than standard-duration therapy (21 mg for 8 weeks)... Background: Tobacco dependence is a chronic, relapsing condition that may require extended treatment. Objective: To assess whether extended-duration transdermal nicotine therapy increases abstinenc...